CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF Diagnosis of Nonischemic Stage B Heart Failure in Type 2 Diabetes Mellitus: Optimal Parameters for Prediction of Heart Failure Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
|<< 1 2 3 4 5 6 7 ...>>|

Clinical TrialDecember 8, 2020 Vol 142, Issue 23

JOURNAL：Circulation. Article Link

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

F Cosentino , CP Cannon , DZI Cherney et al. Keywords: ertugliflozin;T2DM; ASCVD, HF

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top